Cnpharm Co., Ltd.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Mar 2035
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Jan 2, 2027The maintenance fee for Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same (US 10,336,867) comes due Jan 2, 2027. Unpaid by Jul 2, 2027, it lapses early.
- 1 fee due Aug 27, 2027The maintenance fee for Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same (US 11,912,829) comes due Aug 27, 2027. Unpaid by Feb 28, 2028, it lapses early.
- 2 fees due Sep 10 to 17, 2027 · next Sep 10
- 1 fee due Oct 30, 2027The maintenance fee for Metal (HYDR)OXIDE Composite Comprising Poorly Soluble Drug, Method for Manufacturing Same, and Pharmaceutical Composition Comprising Same (US 11,969,440) comes due Oct 30, 2027. Unpaid by May 1, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 9 of 9
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,584,214 | Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same In force · USPTO record | In force | USPTO record | |
| US 10,590,243 | Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same In force · USPTO record | In force | USPTO record | |
| US 11,180,615 | Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same In force · USPTO record | In force | USPTO record | |
| US 11,912,829 | Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same In force · USPTO record | In force | USPTO record | |
| US 10,336,867 | Cationic polyphosphazene compound, polyphosphazenes-drug conjugate compound and method for preparing same In force · USPTO record | In force | USPTO record | |
| US 12,409,229 | Synthesizing drug-organic-acid-anhydride conjugates without using coupling reagent In force · USPTO record | In force | USPTO record | |
| US 11,969,440 | Metal (HYDR)OXIDE Composite Comprising Poorly Soluble Drug, Method for Manufacturing Same, and Pharmaceutical Composition Comprising Same In force · Medium confidence | In force | Medium confidence | |
| US 12,297,213 | Metal hydroxide complex comprising modified multilayer hydroxide structure comprising active ingredient and method of manufacturing same In force · USPTO record | In force | USPTO record | |
| US 12,419,961 | Docetaxel-aconitic anhydride conjugate exhibiting anti-tumor activity without in vivo toxicity In force · USPTO record | In force | USPTO record |
Also on record, not counted in the 9: 1 lapsed for an unpaid fee · 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 5 no status recorded
Showing 1 to 8 of 8, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/216,544 | May 22, 2025 | No status recorded | |
| 18/649,055 | Metal (HYDR) Oxide Composite Comprising Poorly Soluble Drug, Method for Manufacturing Same, and Pharmaceutical Composition Comprising Same | Apr 29, 2024 | Pending |
| 18/587,826 | Novel Cationic Polyphosphazene Compound, Polyphosphazenes-Drug Conjugate Compound and Method for Preparing Same | Feb 26, 2024 | Pending |
| 18/844,666 | Mar 8, 2023 | No status recorded | |
| 18/844,613 | Pharmaceutical Composition Containing Docetaxel or Pharmaceutically Acceptable Salt Thereof and Preparation Method Therefor | Dec 20, 2022 | Pending |
| 17/320,592 | May 14, 2021 | No status recorded | |
| 17/428,111 | Apr 23, 2021 | No status recorded | |
| 13/995,557 | Dec 16, 2011 | No status recorded |